Indication

Kidney disease with reduction in glomerular filtration rate (GFR)

Kidney disease with reduction in glomerular filtration rate (GFR) refers to a clinical state of compromised renal function within the urinary system, characterized by an impaired capacity of the glomeruli to filter metabolic waste and excess fluid from the blood. Read more about Kidney disease with reduction in glomerular filtration rate (GFR)

25 drugs 23 manufacturers

Advertisement

Drugs that treat it

Common Kidney disease with reduction in glomerular filtration rate (GFR) therapies.

Showing 1–9 of 25 drugs

JARDIANCE (empagliflozin)

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+3
Boehringer Ingelheim

FARXIGA (dapagliflozin)

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+4
AstraZeneca Pharmaceuticals

DAPAGLIFLOZIN

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+4
A-S MEDICATION

FARXIGA (dapagliflozin)

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+4
A-S MEDICATION

JARDIANCE (empagliflozin)

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+3
A-S MEDICATION

DAPAGLIFLOZIN

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+4
PRASCO LABS

JARDIANCE (empagliflozin)

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+3
APHENA PHARMA S

DAPAGLIFLOZIN

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+4
BRYANT RANCH PR

DAPAGLIFLOZIN

ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT-2 (SGLT2) INHIBITORS·TYPE 2 DIABETES MELLITUS·+4
AJANTA PHARMA L
Filter & compare in the drug finder →Opens the drug finder with Kidney disease with reduction in glomerular filtration rate (GFR) preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Kidney disease with reduction in glomerular filtration rate (GFR).

Kidney disease with reduction in glomerular filtration rate (GFR) refers to a clinical state of compromised renal function within the urinary system, characterized by an impaired capacity of the glomeruli to filter metabolic waste and excess fluid from the blood.

Commonly manifesting as chronic kidney disease—typically defined by an estimated GFR falling below 60 mL/min/1.73 m² or persisting structural and functional decline for at least three months—it affects diverse patient populations, frequently arising secondary to diabetes, hypertension, or primary glomerulopathies.

Pathophysiologically, the progressive loss of functional nephrons leads to decreased renal clearance, resulting in uremic solute accumulation, disrupted fluid and electrolyte homeostasis, and systemic complications such as anemia, mineral and bone disorders, and heightened cardiovascular risk.

Personalize your experience

Follow Kidney disease with reduction in glomerular filtration rate (GFR) and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it